Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ClearPoint Neuro, Inc. filings document the company's medical-device and therapy-enabling business, including operating results for its brain and spine navigation platforms, CNS drug-delivery services, and neurocritical-care portfolio after the completed IRRAS Holdings acquisition. Form 8-K reports furnish quarterly and annual results, Regulation FD investor presentations, acquisition-related financial statements, pro forma combined financial information, and material-event disclosures.
Proxy materials cover governance matters, director voting, executive compensation, pay-versus-performance data, and equity-award disclosures. The filing record also includes material agreements, capital-structure disclosure, shareholder voting matters, and clinical or regulatory disclosures tied to the company's regulated neurosurgical products and partnered biologics programs.
ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin reported equity award activity involving restricted stock units and common stock. On March 3, 2026, 6,642 restricted stock units were settled into the same number of shares of common stock at $0.00 per share, reflecting a scheduled vesting. In connection with this vesting, 3,380 common shares were delivered back to ClearPoint Neuro at $8.84 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly held 47,732 shares of common stock and 26,568 restricted stock units.
ClearPoint Neuro CEO-related trust reports planned share sale
ClearPoint Neuro, Inc. director and CEO Joseph Burnett reported that a trust for which he serves as trustee sold 19,951 shares of common stock on February 25, 2026 in an open-market transaction at a weighted-average price of $15.17 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 11, 2025. After the sale, the trust-related indirect holding stood at 193,231 shares, while Burnett’s direct ownership was 12,499 shares, reflecting a prior transfer of 934 shares from the trust on February 6, 2026.
CLPT filed a Rule 144 notice reporting securities to be sold through Morgan Stanley Smith Barney LLC. The filing lists 9,156 previously vested restricted stock awards and 12,638 previously vested restricted stock units as securities to be sold.
The filing also discloses recent 10b5-1 sales, including a 20,000 share sale on 01/09/2026 for $322,404.00 and a 2,943 share sale on 01/26/2026 for $45,813.39.
CLPT submitted an amendment to a Form 144/A reporting resale activity in Common stock, including a 10b5-1 sale of 26,463 shares on 10/10/2025 for $714,032.60. The amendment lists prior and planned issuer awards under employee plans with dated grant entries.
ClearPoint Neuro, Inc. reported that Chief Operating Officer Sabra Mazin acquired 36,818 restricted stock units (RSUs) of company stock as a compensation award. Each RSU represents a contingent right to receive one share of CLPT common stock if vesting conditions are met.
The award vests over three years: 20% of the RSUs on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029. After this grant, Mazin directly holds 36,818 RSUs, aligning part of her compensation with the company’s future performance.
STIGALL L. JEREMY reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall received a grant of 51,546 restricted stock units of ClearPoint Neuro common stock. Each unit represents the right to receive one share of CLPT common stock at vesting. The award vests over three years: 20% of the units on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning a substantial portion of his compensation with the company’s long-term performance.
D'Alessandro Danilo reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. reported that Chief Financial Officer Danilo D'Alessandro received a grant of 66,273 restricted stock units. Each unit represents a contingent right to one share of CLPT common stock. The units vest 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029.
ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.
The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.
ClearPoint Neuro filed an amended current report to add detailed financial information for its acquisition of IRRAS Holdings, Inc. The 8-K/A supplies IRRAS’s audited 2024 financial statements, unaudited 2025 interim results, and unaudited pro forma combined financials showing how the two businesses would look if reported together.
The company emphasizes that these pro forma figures are for informational purposes only and do not represent actual historical results or forecasts of future performance after the acquisition.
Bigger Capital Fund LP and related entities filed an amended Schedule 13G reporting their beneficial ownership of ClearPoint Neuro, Inc. common stock as of February 4, 2026. Bigger Capital and its general partner Bigger Capital Fund GP, LLC report beneficial ownership of 1,333,155 shares, or about 4.69% of the outstanding stock.
District 2 Capital Fund LP and its affiliated entities report beneficial ownership of 337,696 shares, or about 1.19%. Michael Bigger may be deemed to beneficially own about 7.8% of the common stock, including interests attributed through these funds and family holdings. The percentages are based on 28,423,308 shares outstanding as of October 27, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control of ClearPoint Neuro.